Application of Gypensapogenin A in drugs for resisting osteoporosis caused by estrogen deficiency

Abstract

The invention discloses a new use of Gypensapogenin A in preventing and curing osteoporosis. The osteoporosis is one of important diseases harming human health. With the ageing of population, patients suffering from the osteoporosis are increasingly, and thus, huge social, medical and economic burdens are brought to the whole world. Although related experts and scholars at home and abroad attach high importance to the prevention and cure of the osteoporosis, effective therapeutic drugs for treating the osteoporosis are lacking. Discovered by in vivo tests, the Gypensapogenin A disclosed by the invention is remarkable in effect of resisting the osteoporosis. Shown by test results, the Gypensapogenin A is capable of remarkably inhibiting bone transformation rate enhancement caused by ovariectomy, reducing bone destruction, and meanwhile, is capable of improving blood calcium concentration, and thereby, the improvement of the blood calcium concentration is in favor of bone deposition. The Gypensapogenin A has a therapeutic effect on the osteoporosis caused by the estrogen deficiency, and has no estrogen-like side effects.

Description

technical field [0001] The invention relates to the field of drugs related to anti-osteoporosis, in particular to the new application of Gypensapogenin A for preventing and treating osteoporosis. Background technique [0002] Osteoporosis is a systemic, metabolic bone disease characterized by reduction and loss of bone mass, bone fragility and increased risk of fracture. With the aging of the population, the incidence of osteoporosis has also increased rapidly, and it has become an important disease that endangers human health and has brought a huge social and economic burden to the world. Although relevant experts and scholars at home and abroad attach great importance to the prevention and treatment of this disease, there is still a lack of effective therapeutic drugs for this disease. [0003] At present, commonly used clinical drugs for the prevention and treatment of osteoporosis include estrogen replacement drugs, bisphosphonates, selective estrogen receptor modulator...

AI Technical Summary

Problems solved by technology

Although bisphosphonates are effective, they can cause serious adverse reactions such as osteonecrosis of the jaw, musculoskeletal pain, and renal failure; although hormone replacement therapy is an important method to prevent and treat postmenopausal osteoporosis, long-term use can cause breast cancer , endometrial cancer potential risk and increased risk of thrombosis; selective estrogen receptor modulators can significantly increase thrombotic events

Other drugs are either expensive or have uncertain long-term curative effects, which are not ideal

Images